Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Detlef H. Krieter has a total of 501 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Comparison of four medium cut-off dialyzers

    by Detlef H Krieter, Christoph Wanner

    Detlef H Krieter, Christoph Wanner; Comparison of four medium cut-off dialyzers, Clinical Kidney Journal, , sfad002, https://doi.org/10.1093/ckj/sfad002


  • Open Access

    Clinical performance comparison of two medium cut‐off dialyzers

    by Detlef H. Krieter, Marieke Rüth, Horst‐Dieter Lemke, Christoph Wanner

    Introduction: Medium‐cut‐off (MCO) dialyzers may beneficially impact outcomes in patients on hemodialysis.Methods: In a randomized, controlled trial in maintenance hemodialysis patients, the new Nipro ELISIO‐17HX MCO dialyzer was compared to the Baxter Theranova 400 filter regarding middle molecule removal. Furthermore, the suitability of two assays for free lambda‐light chain (λFLC) detection (Freelite vs. N‐Latex) was verified.Results: ELISIO‐HX achieved slightly lower reduction ratios for β2‐microglobulin (71.8 ± 6.0 vs. 75.3 ± 5.8%; p = 0.001), myoglobin (54.7 ± 8.6 vs. 64.9 ± 8.7%; p < 0.001), and kappa‐FLC (62.1 ± 8.8 vs. 56.3 ± 7.7%; p = 0.021). λFLC reduction ratios were more conclusive with the Freelite assay and not different between ELISIO‐HX and Theranova (28.4 ± 3.9 vs. 38.7 ± 13.4%; p = 0.069). The albumin loss of Theranova was considerably higher (2.14 ± 0.45 vs. 0.77 ± 0.25 g; p = 0.001) and the Global Removal ScoreLoss alb largely inferior (30.6 ± 7.4 vs. 82.4 ± 29.2%/g; p = 0.006) to ELISIO‐HX.Conclusions: The new ELISIO‐HX expands the choice of dialyzers for MCO hemodialysis.


  • Open Access

    Clinical hemocompatibility of double‐filtration lipoprotein apheresis comparing polyethersulfone and ethylene‐vinyl alcohol copolymer membranes

    by Detlef H. Krieter, Jarline Jeyaseelan, Marieke Rüth, Horst‐Dieter Lemke, Christoph Wanner, Christiane Drechsler

    Introduction Activation of the complement system and leukocytes by blood‐membrane interactions may further promote arteriosclerosis typically present in patients on lipoprotein apheresis. As clinical data on the hemocompatibility of lipoprotein apheresis are scarce, a controlled clinical study comparing two different types of plasma separation and fractionation membranes used in double filtration lipoprotein apheresis was urgently needed, as its outcome may influence clinical decision‐making. Methods In a prospective, randomized, crossover controlled trial, eight patients on double filtration lipoprotein apheresis were subjected to one treatment with recent polyethersulfone (PES) plasma separation and fractionation membranes and one control treatment using a set of ethylene‐vinyl alcohol copolymer (EVAL) membranes. White blood cell (WBC) and platelet (PC) counts, complement factor C5a and thrombin‐anti‐thrombin III (TAT) concentrations were determined in samples drawn at defined times from different sites of the extracorporeal blood and plasma circuit. Results With a nadir at 25 min, WBC in EVAL decreased to 33.5 ± 10.7 % of baseline compared to 63.8 ± 22.0 % at 20 min in PES (P < 0.001). The maximum C5a levels in venous blood re‐entering the patients were measured at 30 min, being 30.0 ± 11.2 µg/L with EVAL and 12.3 ± 9.0 µg/L with PES (P < 0.05). The highest C5a concentrations were found in plasma after the plasma filters (EVAL 56.1 ± 22.0 µg/L at 15 min vs. PES 23.3 ± 15.2 µg/L at 10 min; P < 0.001). PC did not significantly decrease over time with both membrane types, while TAT levels did not rise until the end of the treatment without differences between membranes. Regarding lipoprotein(a) and LDL cholesterol removal, both membrane sets performed equally. Conclusion Compared to EVAL, PES membranes cause less leukocyte and complement system activation, the classical parameters of hemocompatibility of extracorporeal treatment procedures, at identical treatment efficacy. Better hemocompatibility may avoid inflammation‐promoting effects through blood‐material interactions in patients requiring double‐filtration lipoprotein apheresis.


  • Open Access

    Differences in Dialysis Efficacy Have Limited Effects on Protein-Bound Uremic Toxins Plasma Levels over Time

    by Detlef H. Krieter, Simon Kerwagen, Marieke Rüth, Horst-Dieter Lemke, Christoph Wanner

    The protein-bound uremic toxins para-cresyl sulfate (pCS) and indoxyl sulfate (IS) are associated with cardiovascular disease in chronic renal failure, but the effect of different dialysis procedures on their plasma levels over time is poorly studied. The present prospective, randomized, cross-over trial tested dialysis efficacy and monitored pre-treatment pCS and IS concentrations in 15 patients on low-flux and high-flux hemodialysis and high-convective volume postdilution hemodiafiltration over six weeks each. Although hemodiafiltration achieved by far the highest toxin removal, only the mean total IS level was decreased at week three (16.6 ± 12.1 mg/L) compared to baseline (18.9 ± 13.0 mg/L, p = 0.027) and to low-flux dialysis (20.0 ± 12.7 mg/L, p = 0.021). At week six, the total IS concentration in hemodiafiltration reached the initial values again. Concentrations of free IS and free and total pCS remained unaltered. Highest beta2-microglobulin elimination in hemodiafiltration (p < 0.001) led to a persistent decrease of the plasma levels at week three and six (each p < 0.001). In contrast, absent removal in low-flux dialysis resulted in rising beta2-microglobulin concentrations (p < 0.001). In conclusion, this trial demonstrated that even large differences in instantaneous protein-bound toxin removal by current extracorporeal dialysis techniques may have only limited impact on IS and pCS plasma levels in the longer term.


  • Characterization of Fractionation Membranes in an Animal Model of Double Filtration Lipoprotein Apheresis

    by Detlef H Krieter, Florian Lange, Horst‐Dieter Lemke, Florian Bonn, Christoph Wanner

    Technical problems during clinical lipid apheresis interfere with fractionator performance. Therefore, a large animal model was established to characterize a new plasma fractionation membrane. Four sheep were randomized, controlled, and crossover subjected to double ofiltration lipoprotein apheresis with three specimens of FractioPESR having slightly different HDL sieving coefficients (SK) (FPESa, 0.30, FPESb, 0.26, and FPESc, 0.22) versus a control fractionator (EVAL). SK and reduction ratios were determined for LDL, HDL, fibrinogen, IgG, and albumin. Compared to EVAL (0.42 ± 0.04 to 0.74 ± 0.08) and FPESa (0.36 ± 0.06 to 0.64 ± 0.04), SK for HDL were lower (P < 0.05) with FPESc (0.30 ± 0.04 to 0.49 ± 0.10). Fibrinogen SK were higher (P < 0.05) with EVAL (0.02 ± 0.01 to 0.40 ± 0.08) compared to FPESb (0.05 ± 0.02 to 0.26 ± 0.34) and FPESc (0.01 ± 0.01 to 0.21 ± 0.16). No further differences were determined. The animal model distinguished between minor differences in fractionation membrane permeability, demonstrating equivalent sieving of FPESa and EVAL and slightly inferior permeability of FPESb and FPESc.

  • Haemodiafiltration at increased plasma ionic strength for improved protein‐bound toxin removal

    by Detlef H. Krieter, Eric Devine, Thomas Körner, Marieke Rüth, Christoph Wanner, Manuelle Raine, Joachim Jankowski, Horst‐Dieter Lemke

    Aim: Protein‐bound uraemic toxin accumulation causes uraemia‐associated cardiovascular morbidity. Enhancing the plasma ionic strength releases toxins from protein binding and makes them available for removal during dialysis. This concept was implemented through high sodium concentrations ([Na+]) in the substituate of pre‐dilution haemodiafiltration at increased plasma ionic strength (HDF‐IPIS).Methods: Ex vivo HDF‐IPIS with blood tested increasing [Na+] to demonstrate efficacy and haemocompatibility. Haemocompatibility was further assessed in sheep using two different HDF‐IPIS set‐ups and [Na+] between 350 and 600 mmol L−1. Safety and efficacy of para‐cresyl sulphate (pCS) and indoxyl sulphate (IS) removal was further investigated in a randomized clinical pilot trial comparing HDF‐IPIS to HD and HDF.Results: Compared to [Na+] of 150 mmol L−1, ex vivo HDF‐IPIS at 500 mmol L−1 demonstrated up to 50% higher IS removal. Haemolysis in sheep was low even at [Na+] of 600 mmol L−1 (free Hb 0.016 ± 0.001 g dL−1). In patients, compared to HD, a [Na+] of 240 mmol L−1 in HDF‐IPIS resulted in 40% greater reduction (48.7 ± 23.6 vs. 67.8 ± 7.9%; P = 0.013) in free IS. Compared to HD and HDF (23.0 ± 14.8 and 25.4 ± 10.5 mL min−1), the dialytic clearance of free IS was 31.6 ± 12.8 mL min−1 (P = 0.017) in HDF‐IPIS, but [Na+] in arterial blood increased from 132 ± 2 to 136 ± 3 mmol L−1 (0 vs. 240 min; P < 0.001).Conclusion: HDF‐IPIS is technically and clinically feasible. More effective HDF‐IPIS requires higher temporary plasma [Na+], but dialysate [Na+] has to be appropriately adapted to avoid sodium accumulation.


  • Pharmacokinetics of Certoparin During In Vitro and In Vivo Dialysis

    by Detlef H. Krieter, Susanne Fink, Oliver Dorsch, Job Harenberg, Nima Melzer, Christoph Wanner, Horst‐Dieter Lemke

    The efficacy and safety of certoparin in the prophylaxis of clotting during hemodialysis have recently been proven. Different to other low‐molecular weight heparins (LMWHs), certoparin does not accumulate in maintenance dialysis patients for unknown reasons. The purpose of the present study was to examine the impact of the dialysis procedure on the removal of certoparin. In a subgroup of the MEMBRANE study consisting of 12 patients, the pharmacokinetics of certoparin during hemodialysis was determined by means of the anti‐Xa activity. In addition, the elimination of certoparin into continuously collected dialysate was assessed. Further, in vitro experiments with human blood‐simulating high‐flux hemodialysis and hemofiltration were performed to quantify the elimination and the sieving coefficients SK of the two LMWHs certoparin and enoxaparin compared with unfractionated heparin (UFH). The surrogate marker middle molecules inulin and myoglobin served as reference solutes during the experiments. Finally, the adsorption of 125iodine‐radiolabeled certoparin onto the synthetic dialysis membrane was quantified. The clinical study reconfirmed the absence of bioaccumulation of certoparin with anti‐Xa activities between SK of both LMWH and UFH was very low in hemofiltration and particularly in hemodialysis with values ≤0.1. The elimination kinetics during hemodialysis suggests strong protein‐binding of certoparin. Different from LMWH significantly cleared by the kidneys, the relatively short half‐life time of certoparin of only 2 h during hemodialysis allows a more reliable control of the anti‐coagulatory effects and decreases the risk of bleeding complications. Dialytic removal does not significantly contribute to the clearance of certoparin in maintenance dialysis patients.


  • Open Access

    Binding Affinity and Capacity for the Uremic Toxin Indoxyl Sulfate

    by Eric Devine, Detlef H. Krieter, Marieke Rüth, Joachim Jankovski, Horst-Dieter Lemke

    Protein binding prevents uremic toxins from removal by conventional extracorporeal therapies leading to accumulation in maintenance dialysis patients. Weakening of the protein binding may enhance the dialytic elimination of these toxins. In ultrafiltration and equilibrium dialysis experiments, different measures to modify the plasma binding affinity and capacity were tested: (i), increasing the sodium chloride (NaCl) concentration to achieve a higher ionic strength; (ii), increasing the temperature; and (iii), dilution. The effects on the dissociation constant KD and the protein bound fraction of the prototypical uremic toxin indoxyl sulfate (IS) in plasma of healthy and uremic individuals were studied. Binding of IS corresponded to one site binding in normal plasma. KD increased linearly with the NaCl concentration between 0.15 (KD = 13.2 ± 3.7 µM) and 0.75 M (KD = 56.2 ± 2.0 µM). Plasma dilution further reduced the protein bound toxin fraction by lowering the protein binding capacity of the plasma. Higher temperatures also decreased the protein bound fraction of IS in human plasma. Increasing the NaCl concentration was effective to weaken the binding of IS also in uremic plasma: the protein bound fraction decreased from 89% ± 3% to 81% ± 3% at 0.15 and 0.75 M NaCl, respectively. Dilution and increasing the ionic strength and temperature enhance the free fraction of IS allowing better removal of the substance during dialysis. Applied during clinical dialysis, this may have beneficial effects on the long-term outcome of maintenance dialysis patients.


  • Clearance of Drugs for Multiple Myeloma Therapy During In Vitro High-Cutoff Hemodialysis

    by Detlef H. Krieter, Eric Devine, Christoph Wanner, Markus Storr, Bernd Krause, Horst-Dieter Lemke

    Current chemotherapy for multiple myeloma is based on bortezomib ( BOR ), dexamethasone ( DEX ), and thalidomide ( THA ). The purpose of the present study was to examine their clearance during high‐cutoff ( HCO ) hemodialysis and to accordingly apply the results to the dialytic removal of protein‐bound substances in general. During in vitro hemodialysis with human blood (blood, dialysate, and ultrafiltration flow rates 250, 500 and 5 mL/min, respectively) comparing a highly permeable HCO dialyzer ( T heralite, 2.1 m 2 ) to a high‐flux dialyzer ( PFX ; 2.1 m 2 ), ultrafiltered volume was replaced by saline containing 30 g/L urea. After recirculation for equilibration, BOR was injected, and arterial and venous samples were drawn after 10, 11, and 12 min to measure the plasma clearance ( K ) of both urea and BOR . The same procedure was performed with THA and DEX . By mathematical simulation, the influence of varying plasma albumin concentrations ( C HSA ) on the protein‐bound drug fraction ( PBF ) and K was assessed. Plasma K values of HCO and PFX for THA , BOR , and DEX were about 40% (80 ± 7 vs. 65 ± 6 mL/min; P < 0.05), 70% (40 ± 8 vs. 33 ± 4 mL/min; P < 0.05), and 65% (47 ± 11 vs. 38 ± 7 mL/min; P < 0.05), respectively—lower ( P < 0.0001) compared with urea (125 ± 7 vs. 122 ± 5 mL/min). K was highest ( P < 0.0001) for THA . K was negatively correlated with C HSA ( THA , r 2 = 0.58, P < 0.001; BOR , r 2 = 0.24, P < 0.05; DEX , r 2 = 0.22, P < 0.05). C HSA continually decreased ( P < 0.05) over time only with HCO , resulting in lower calculated PBF . Compared with BOR and DEX (minimum 72 and 56%, respectively), the PBF of THA (37%) was significantly lower ( P < 0.001). A mathematical simulation based on the K values of urea and the drugs reliably estimated PBF ( r 2 = 0.886, P < 0.001). Drugs for multiple myeloma therapy are significantly removed with both HCO and PFX , with important implications for the dosing and timing of administration, particularly in patients with cast nephropathy receiving extended dialysis. If the K urea of a dialyzer and the PBF of any given drug are known, K drug can be reliably estimated by mathematical simulation.


  • Open Access

    BisphenolAin Chronic Kidney Disease

    by Detlef H. Krieter, Bernard Canaud, Horst‐Dieter Lemke, Annie Rodriguez, Andreas Morgenroth, Kai von Appen, Gerd‐Peter Dragoun, Christoph Wanner

    The estrogenic endocrine‐disrupting substance bisphenolA(BPA) is extensively used as a starting material for a variety of consumer plastic products including dialyzer materials. The present study was performed to explore plasmaBPAlevels in patients with impaired renal function and to investigate if dialyzers differing in elutableBPAinfluence plasma levels in patients on maintenance hemodialysis. In vitroBPAwas eluted from high‐flux polyethersulfone (PUREMA H, referred asPUR‐H), high‐flux polysulfone (referred asHF‐PSu), and low‐flux polysulfone (referred asLF‐PSu) dialyzers by recirculation with water for 180 min. In a cross‐sectional clinical study, plasmaBPAlevels of outpatients with different stages of chronic kidney disease (CKD) from four different centers were determined. Furthermore, in a prospective, randomized, and crossover setting, 18 maintenance dialysis patients were subjected successively to 4 weeks of thrice‐weekly hemodialysis with eachLF‐PSu,HF‐PSu, andPUR‐H. In addition, the fractions of protein‐bound and freeBPAwere determined in a subset of dialysis patients. The mass ofBPAeluted from the blood compartments in vitro under aqueous conditions varied for the three dialyzers being very low forPUR‐H(6.2 ± 2.5 ng;P < 0.001), intermediate forHF‐PSu(48.1 ± 7.7 ng), and highest forLF‐PSu(140.8 ± 38.7 ng;P < 0.01). In 152 prevalent patients withCKDenrolled in the cross‐sectional trial, plasmaBPAstarted to rise after stage 3. Maintenance hemodialysis patients had more than six times higherBPAconcentrations than patients withCKDstage 5 not yet on dialysis (10.0 ± 6.6 vs. 1.6 ± 1.8 ng/mL;P < 0.001). TheBPAconcentrations highly and inversely correlated with renal function. In the randomized controlled study, the plasmaBPAconcentrations were highly elevated compared with healthy controls (range 9.1 ± 4.5–12.0 ± 6.0 ng/mL vs. ≤0.2 ± 0.1 ng/mL;P < 0.001), but no change of the plasma levels was observed during hemodialysis with any of the three dialyzers in the course of a single treatment and over a period of 4 weeks. The protein‐bound fraction of plasmaBPAin the dialysis patients was 74 ± 5%. Renal function and, most likely, the total quantity of ingestedBPAare essential parameters affecting plasmaBPAconcentrations. Dialyzers are one additional source ofBPA, but differences in the elutableBPAcontent are not associated with a significant effect onBPAplasma levels in Western European maintenance dialysis patients. Due to high protein binding, the removal ofBPAby hemodialysis is limited.